Aprea Therapeutics, Inc. (APRE)
| Market Cap | 6.31M -22.6% |
| Revenue (ttm) | 5,185 -99.4% |
| Net Income | -12.31M |
| EPS | -0.60 |
| Shares Out | 12.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35,456 |
| Open | 0.4875 |
| Previous Close | 0.4910 |
| Day's Range | 0.4800 - 0.5014 |
| 52-Week Range | 0.4100 - 1.4900 |
| Beta | 1.69 |
| Analysts | Strong Buy |
| Price Target | 3.30 (+558.29%) |
| Est. Earnings | Nov 16, 2026 |
About APRE
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in ... [Read more]
Financial Performance
In 2025, Aprea Therapeutics's revenue was $285,759, a decrease of -80.98% compared to the previous year's $1.50 million. Losses were -$12.60 million, -2.77% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for APRE stock is "Strong Buy." The 12-month stock price target is $3.3, which is an increase of 558.29% from the latest price.
News
Aprea Therapeutics Transcript: Pre-ESMO Virtual Panel Conference
WEE1 inhibition may exploit DNA-repair vulnerabilities in biomarker-defined cancers, but clinical potential depends on manageable toxicity and durable activity. APR-1051’s fall trial update was expected to report enrollment and patient experience.
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
DOYLESTOWN, Pa., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery an...
Aprea Therapeutics initiated with a Buy at Ladenburg
Ladenburg initiated coverage of Aprea Therapeutics (APRE) with a Buy rating and $2 price target
Aprea Therapeutics to Present at October Conferences
Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15) Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechn...
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
DOYLESTOWN, Pa., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery a...
Aprea Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The session highlighted progress in synthetic lethality oncology, with a WEE1 inhibitor showing promising efficacy and safety in biomarker-defined cancers. Dose escalation established 150 mg as the minimum efficacious dose, and further data updates are expected in Q4.
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
DOYLESTOWN, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery a...
Aprea Therapeutics provides update on existing patent portfolio
Aprea Therapeutics (APRE) provided an update on its existing patent portfolio. The intellectual property covering Aprea’s WEE1 kinase inhibitor program includes two pending U.S. patent applications, o...
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents
Aprea Therapeutics reports Q2 EPS (7c), consensus (22c)
“Having observed early signs of clinical activity for APR-1051, we are now expanding the ongoing ACESOT-1051 trial,” said Oren Gilad, President and Chief Executive Officer of Aprea. “We are accelerati...
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances
Aprea Therapeutics Earnings release: Q2 2026
Aprea Therapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Aprea Therapeutics Quarterly report: Q2 2026
Aprea Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Aprea Therapeutics Slides: Corporate presentation
Aprea Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical pr...
Aprea Therapeutics Transcript: AGM 2026
The meeting covered director elections, auditor ratification, a reverse stock split, and executive compensation, with all proposals approved by stockholders. No questions were raised, and final voting results will be filed in a Form 8-K.
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor types Manageable tolerability confirmed across cohort...
Aprea Therapeutics price target lowered to $6 from $7 at Wedbush
Wedbush analyst Robert Driscoll lowered the firm’s price target on Aprea Therapeutics (APRE) to $6 from $7 and keeps an Outperform rating on the shares. The firm notes the company…
Aprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year
As of March 31 the Company reported cash and cash equivalents of $46.5M compared to $14.6M as of December 31, 2025. The Company believes that its cash will be sufficient…
Aprea Therapeutics Earnings release: Q1 2026
Aprea Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Aprea Therapeutics Quarterly report: Q1 2026
Aprea Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and...
Aprea Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Aprea Therapeutics (APRE) with an Outperform rating and $5 price target The firm cites the potential of the company’s WEE1 inhibitor APR-1051 and the stock’s “sizable...
Aprea Therapeutics Proxy statement: Proxy filing
Aprea Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Aprea Therapeutics Proxy statement: Proxy filing
Aprea Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.